Logo image of KPRX

KIORA PHARMACEUTICALS INC (KPRX) Stock Fundamental Analysis

NASDAQ:KPRX - Nasdaq - US49721T5074 - Common Stock - Currency: USD

3.22  -0.07 (-2.08%)

Fundamental Rating

5

KPRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While KPRX has a great health rating, its profitability is only average at the moment. KPRX is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year KPRX was profitable.
In the past year KPRX had a positive cash flow from operations.
In the past 5 years KPRX reported 4 times negative net income.
In the past 5 years KPRX reported 4 times negative operating cash flow.
KPRX Yearly Net Income VS EBIT VS OCF VS FCFKPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of 9.85%, KPRX belongs to the top of the industry, outperforming 92.93% of the companies in the same industry.
With an excellent Return On Equity value of 13.95%, KPRX belongs to the best of the industry, outperforming 89.39% of the companies in the same industry.
KPRX has a better Return On Invested Capital (13.58%) than 89.39% of its industry peers.
Industry RankSector Rank
ROA 9.85%
ROE 13.95%
ROIC 13.58%
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
KPRX Yearly ROA, ROE, ROICKPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

With an excellent Profit Margin value of 22.44%, KPRX belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
KPRX has a Operating Margin of 40.69%. This is amongst the best in the industry. KPRX outperforms 96.97% of its industry peers.
Industry RankSector Rank
OM 40.69%
PM (TTM) 22.44%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KPRX Yearly Profit, Operating, Gross MarginsKPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

KPRX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
KPRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KPRX has more shares outstanding
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KPRX Yearly Shares OutstandingKPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
KPRX Yearly Total Debt VS Total AssetsKPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

KPRX has an Altman-Z score of -3.15. This is a bad value and indicates that KPRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of KPRX (-3.15) is comparable to the rest of the industry.
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -3.15
ROIC/WACC1.43
WACC9.5%
KPRX Yearly LT Debt VS Equity VS FCFKPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

KPRX has a Current Ratio of 4.94. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.94, KPRX is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
A Quick Ratio of 4.94 indicates that KPRX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.94, KPRX is doing good in the industry, outperforming 73.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.94
Quick Ratio 4.94
KPRX Yearly Current Assets VS Current LiabilitesKPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

7

3. Growth

3.1 Past

KPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 103.67%, which is quite impressive.
The Revenue has been growing by 42.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)103.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 40.29% on average over the next years. This is a very strong growth
KPRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.09% yearly.
EPS Next Y-355.98%
EPS Next 2Y-111.92%
EPS Next 3Y-66.42%
EPS Next 5Y40.29%
Revenue Next Year-82.1%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
KPRX Yearly Revenue VS EstimatesKPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2024 2025 2026 2028 2029 2030 2031 2032 100M 200M 300M
KPRX Yearly EPS VS EstimatesKPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2K -4K -6K -8K -10K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

KPRX is valuated cheaply with a Price/Earnings ratio of 3.10.
Compared to the rest of the industry, the Price/Earnings ratio of KPRX indicates a rather cheap valuation: KPRX is cheaper than 97.47% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 28.88. KPRX is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for KPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 3.1
Fwd PE N/A
KPRX Price Earnings VS Forward Price EarningsKPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, KPRX is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.13
EV/EBITDA -6.14
KPRX Per share dataKPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as KPRX's earnings are expected to decrease with -66.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-111.92%
EPS Next 3Y-66.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KIORA PHARMACEUTICALS INC

NASDAQ:KPRX (4/30/2025, 8:17:58 PM)

3.22

-0.07 (-2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)05-08 2025-05-08
Inst Owners37.31%
Inst Owner Change0%
Ins Owners2.16%
Ins Owner Change16.52%
Market Cap9.66M
Analysts82.5
Price Target11.22 (248.45%)
Short Float %1.17%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-44.66%
Min EPS beat(2)-85.38%
Max EPS beat(2)-3.94%
EPS beat(4)2
Avg EPS beat(4)153.62%
Min EPS beat(4)-85.38%
Max EPS beat(4)664.47%
EPS beat(8)4
Avg EPS beat(8)65.82%
EPS beat(12)6
Avg EPS beat(12)41.79%
EPS beat(16)9
Avg EPS beat(16)22.39%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40.54%
PT rev (3m)-63.74%
EPS NQ rev (1m)-14.93%
EPS NQ rev (3m)-3.36%
EPS NY rev (1m)-4.61%
EPS NY rev (3m)-11.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)50%
Valuation
Industry RankSector Rank
PE 3.1
Fwd PE N/A
P/S 0.6
P/FCF 1.13
P/OCF 1.13
P/B 0.38
P/tB 0.51
EV/EBITDA -6.14
EPS(TTM)1.04
EY32.3%
EPS(NY)-2.66
Fwd EYN/A
FCF(TTM)2.85
FCFY88.54%
OCF(TTM)2.85
OCFY88.6%
SpS5.34
BVpS8.59
TBVpS6.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.85%
ROE 13.95%
ROCE 21.39%
ROIC 13.58%
ROICexc 112.39%
ROICexgc N/A
OM 40.69%
PM (TTM) 22.44%
GM N/A
FCFM 53.39%
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 32.81%
Cap/Sales 0.04%
Interest Coverage 250
Cash Conversion 130.92%
Profit Quality 237.93%
Current Ratio 4.94
Quick Ratio 4.94
Altman-Z -3.15
F-Score8
WACC9.5%
ROIC/WACC1.43
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.41%
EPS Next Y-355.98%
EPS Next 2Y-111.92%
EPS Next 3Y-66.42%
EPS Next 5Y40.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A
Revenue Next Year-82.1%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
EBIT growth 1Y160.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y189.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y189.56%
OCF growth 3YN/A
OCF growth 5YN/A